{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T01:40:26Z","timestamp":1776908426888,"version":"3.51.2"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["FRM ARF201809006989"],"award-info":[{"award-number":["FRM ARF201809006989"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["00120250\/WB-2021-33281"],"award-info":[{"award-number":["00120250\/WB-2021-33281"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["PJA 20191209328"],"award-info":[{"award-number":["PJA 20191209328"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00e9gion Provence-Alpes-C\u00f4te d\u2019Azur \u201cEmplois jeunes doctorants\u201d"},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"La Ligue contre le cancer CD94\/Val de Marne"},{"name":"French government, INSERM INCA PLBio"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, we conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin regulators. We revealed that the lysine methyltransferase, SETDB1, plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 deficiency induces a DNA damage response, senescence-like state and growth arrest. Knockdown of SETDB1 is associated with a decreased expression of genes related to replication and cell cycle. Moreover, deficiency in CDC6, an essential regulator of DNA replication, phenocopies SETDB1 inhibition. Using a pre-clinical model, we further demonstrated that anti-SETDB1 therapy impairs tumor growth in vivo. Therefore, we not only provide evidence that SETDB1 plays a critical role in metastatic uveal melanoma cell growth, but we also identify SETDB1 as a novel relevant therapeutic target for the treatment of metastatic uveal melanoma.<\/jats:p>","DOI":"10.1038\/s41419-025-08084-z","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:35:51Z","timestamp":1761320151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target"],"prefix":"10.1038","volume":"16","author":[{"given":"Im\u00e8ne","family":"Krossa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Pisibon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9839-4332","authenticated-orcid":false,"given":"Yann","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Bille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Dalmasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabah","family":"Hamadat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystel","family":"Husser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Irondelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-1527","authenticated-orcid":false,"given":"Julien","family":"Cherfils-Vicini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Soysouvanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacha","family":"Nahon-Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Caujolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia","family":"Maschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Baillif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul","family":"Carcamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-3244","authenticated-orcid":false,"given":"Andrew E.","family":"Aplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6533-8326","authenticated-orcid":false,"given":"Emily","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-8712","authenticated-orcid":false,"given":"Valeria","family":"Naim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ballotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6252-0181","authenticated-orcid":false,"given":"Thomas","family":"Strub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"8084_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1101\/gad.296962.117","volume":"31","author":"C Pandiani","year":"2017","unstructured":"Pandiani C, B\u00e9ranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31:724\u201343.","journal-title":"Genes Dev"},{"key":"8084_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"8084_CR3","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389:2256\u201366.","journal-title":"N Engl J Med"},{"key":"8084_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204\u201320.e15.","journal-title":"Cancer Cell"},{"key":"8084_CR5","doi-asserted-by":"crossref","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson BR, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20:99\u2013115.","DOI":"10.1038\/s41571-022-00714-1"},{"key":"8084_CR6","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133.","journal-title":"Science"},{"key":"8084_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","volume":"465","author":"JC Scheuermann","year":"2010","unstructured":"Scheuermann JC, Alonso AG, de A, Oktaba K, Ly-Hartig N, McGinty RK, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465:243\u20137.","journal-title":"Nature"},{"key":"8084_CR8","doi-asserted-by":"crossref","unstructured":"Strub T, Ballotti R, Bertolotto C. The \u201cART\u201d of epigenetics in melanoma: from histone \u201calterations, to resistance and therapies.\u201d Theranostics. 2020;10:1777\u201397.","DOI":"10.7150\/thno.36218"},{"key":"8084_CR9","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.3390\/cancers13194763","volume":"13","author":"G Levidou","year":"2021","unstructured":"Levidou G, Gajdzis P, Cassoux N, Donizy P, Masaoutis C, Gajdzis M, et al. Histone deacetylase (HDAC)-1, -2, -4, and -6 in uveal melanomas: associations with clinicopathological parameters and patients\u2019 survival. Cancers (Basel). 2021;13:4763.","journal-title":"Cancers (Basel)"},{"key":"8084_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11081132","volume":"11","author":"Z Souri","year":"2019","unstructured":"Souri Z, Wierenga APA, Mulder A, Jochemsen AG, Jager MJ. HLA expression in uveal melanoma: an indicator of malignancy and a modifiable immunological target. Cancers. 2019;11:1\u201318.","journal-title":"Cancers"},{"key":"8084_CR11","doi-asserted-by":"crossref","unstructured":"Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, et al. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. Mol Cancer Res. 2020;19:1\u20139.","DOI":"10.1158\/1541-7786.MCR-20-0434"},{"key":"8084_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpha.2022.11.008","volume":"13","author":"X Gu","year":"2023","unstructured":"Gu X, Hua Y, Yu J, Yang L, Ge S, Jia R, et al. Epigenetic drug library screening reveals targeting DOT1L abrogates NAD+ synthesis by reprogramming H3K79 methylation in uveal melanoma. J Pharm Anal. 2023;13:24\u201338.","journal-title":"J Pharm Anal"},{"key":"8084_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/iovs.65.2.27","volume":"65","author":"MC Herwig-Carl","year":"2024","unstructured":"Herwig-Carl MC, Sharma A, Tischler V, Pelusi N, Loeffler KU, Holz FG, et al. Mass spectrometry-based profiling of histone post-translational modifications in uveal melanoma tissues, human melanocytes, and uveal melanoma cell lines - A pilot study. Invest Ophthalmol Vis Sci. 2024;65:27.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8084_CR14","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/1535-7163.MCT-19-1013","volume":"19","author":"F Rago","year":"2020","unstructured":"Rago F, Elliott G, Li A, Sprouffske K, Kerr G, Desplat A, et al. The discovery of SWI\/SNF chromatin remodeling activity as a novel and targetable dependency in uveal melanoma. Mol Cancer Ther. 2020;19:2186\u201395.","journal-title":"Mol Cancer Ther"},{"key":"8084_CR15","first-page":"1","volume":"9","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wu S. RUVBL1-modulated chromatin remodeling alters the transcriptional activity of oncogenic CTNNB1 in uveal melanoma. Cell Death Discov. 2023;9:1\u201311.","journal-title":"Cell Death Discov"},{"key":"8084_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05966-z","volume":"9","author":"T Strub","year":"2018","unstructured":"Strub T, Ghiraldini FG, Carcamo S, Li M, Wroblewska A, Singh R, et al. SIRT6 haploinsufficiency induces BRAF(V600E) melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun. 2018;9:3440.","journal-title":"Nat Commun"},{"key":"8084_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/0008-5472.CAN-20-2906","volume":"81","author":"D Strepkos","year":"2021","unstructured":"Strepkos D, Markouli M, Klonou A, Papavassiliou AG, Piperi C. Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential. Cancer Res. 2021;81:525\u201334.","journal-title":"Cancer Res"},{"key":"8084_CR18","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1073\/pnas.95.7.3603","volume":"95","author":"Z Yan","year":"1998","unstructured":"Yan Z, Degregori J, Shohet R, Leone G, Stillman B, Nevins JR, et al. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA. 1998;95:3603\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8084_CR19","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.18632\/aging.101917","volume":"11","author":"E B\u00e1rtov\u00e1","year":"2019","unstructured":"B\u00e1rtov\u00e1 E, Legartov\u00e1 S, Dundr M, Such\u00e1nkov\u00e1 J. A role of the 53BP1 protein in genome protection: structural and functional characteristics of 53BP1-dependent DNA repair. Aging (Albany NY). 2019;11:2488\u2013511.","journal-title":"Aging (Albany NY)"},{"key":"8084_CR20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1909","volume":"11","author":"F Rodier","year":"2009","unstructured":"Rodier F, Copp\u00e9 JP, Patil CK, Hoeijmakers WAM, Mu\u00f1oz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973\u20139.","journal-title":"Nat Cell Biol"},{"key":"8084_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nrm4002","volume":"16","author":"M Fragkos","year":"2015","unstructured":"Fragkos M, Ganier O, Coulombe P, M\u00e9chali M. DNA replication origin activation in space and time. Nat Rev Mol Cell Biol. 2015;16:360\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8084_CR22","doi-asserted-by":"publisher","first-page":"19176","DOI":"10.1073\/pnas.0606373103","volume":"103","author":"H Ryu","year":"2016","unstructured":"Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, et al. ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington\u2019s disease. Proc Natl Acad Sci USA. 2016;103:19176\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8084_CR23","doi-asserted-by":"crossref","unstructured":"Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, et al. Mithramycin Is A Gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci. 2011;31:6858\u201370.","DOI":"10.1523\/JNEUROSCI.0710-11.2011"},{"key":"8084_CR24","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1002\/anie.202017200","volume":"60","author":"Y Guo","year":"2021","unstructured":"Guo Y, Mao X, Xiong L, Xia A, You J, Lin G, et al. Structure-guided discovery of a potent and selective cell-active inhibitor of SETDB1 tudor domain. Angew Chem Int Ed Engl. 2021;60:8760\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"key":"8084_CR25","doi-asserted-by":"crossref","unstructured":"Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21:413\u201330.","DOI":"10.1038\/s41568-021-00357-x"},{"key":"8084_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nature06166","volume":"449","author":"E Guccione","year":"2007","unstructured":"Guccione E, Bassi C, Casadio F, Martinato F, Cesaroni M, Schuchlautz H, et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature. 2007;449:933\u20137.","journal-title":"Nature"},{"key":"8084_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature09806","volume":"471","author":"CJ Ceol","year":"2011","unstructured":"Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471:513\u20137.","journal-title":"Nature"},{"key":"8084_CR28","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1002\/ijc.32432","volume":"145","author":"E Orouji","year":"2019","unstructured":"Orouji E, Federico A, Larrib\u00e8re L, Novak D, Lipka DB, Assenov Y, et al. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. Int J Cancer. 2019;145:3462\u201377.","journal-title":"Int J Cancer"},{"key":"8084_CR29","doi-asserted-by":"crossref","unstructured":"Shi X, Tasdogan A, Huang F, Hu Z, Morrison SJ, DeBerardinis RJ. The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 2017;3:eaao5268.","DOI":"10.1126\/sciadv.aao5268"},{"key":"8084_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12017-013-8254-x","volume":"16","author":"A Spyropoulou","year":"2014","unstructured":"Spyropoulou A, Gargalionis A, Dalagiorgou G, Adamopoulos C, Papavassiliou KA, Lea RW, et al. Role of histone lysine Methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and Colony formation. Neuromolecular med. 2014;16:70\u201382.","journal-title":"Neuromolecular med"},{"key":"8084_CR31","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1038\/onc.2013.239","volume":"33","author":"M Rodriguez-Paredes","year":"2014","unstructured":"Rodriguez-Paredes M, de Paz AM, Sim\u00f3-Riudalbas L, Sayols S, Moutinho C, Moran S, et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene. 2014;33:2807\u201313.","journal-title":"Oncogene"},{"key":"8084_CR32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.28304","volume":"63","author":"CM Wong","year":"2015","unstructured":"Wong CM, Wei L, Law CT, Ho DWH, Tsang FHC, Au SLK, et al. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology. 2015;63:474\u201387.","journal-title":"Hepatology"},{"key":"8084_CR33","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Atlas NCG.","year":"2015","unstructured":"Atlas NCG. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"8084_CR34","doi-asserted-by":"publisher","first-page":"130377","DOI":"10.1016\/j.bbagen.2023.130377","volume":"1867","author":"W Li","year":"2023","unstructured":"Li W, Yang X, Liu X, Deng H, Li W, He X, et al. SETDB1 confers colorectal cancer metastasis by regulation of WNT\/\u03b2-catenin signaling. Biochim Biophys Acta (BBA) - Gen Subj. 2023;1867:130377.","journal-title":"Biochim Biophys Acta (BBA) - Gen Subj"},{"key":"8084_CR35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1073\/pnas.032677499","volume":"99","author":"JG Cook","year":"2002","unstructured":"Cook JG, Park CH, Burke TW, Leone G, DeGregori J, Engel A, et al. Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci. 2002;99:1347\u201352.","journal-title":"Proc Natl Acad Sci"},{"key":"8084_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-024-05855-w","volume":"7","author":"AK Yadav","year":"2024","unstructured":"Yadav AK, Polasek-Sedlackova H. Quantity and quality of minichromosome maintenance protein complexes couple replication licensing to genome integrity. Commun Biol. 2024;7:1\u201314.","journal-title":"Commun Biol"},{"key":"8084_CR37","doi-asserted-by":"publisher","first-page":"10899","DOI":"10.1158\/0008-5472.CAN-07-2837","volume":"67","author":"M Liontos","year":"2007","unstructured":"Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, et al. Cancer, Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res. 2007;67:10899\u2013909.","journal-title":"Cancer Res"},{"key":"8084_CR38","first-page":"1063","volume":"8","author":"S Ohta","year":"2001","unstructured":"Ohta S, Koide M, Tokuyama T, Yokota N, Nishizawa S, Namba H. Cdc6 expression as a marker of proliferative activity in brain tumors. Oncol Rep. 2001;8:1063\u20136.","journal-title":"Oncol Rep"},{"key":"8084_CR39","doi-asserted-by":"publisher","first-page":"40362","DOI":"10.18632\/oncotarget.9616","volume":"7","author":"S Chen","year":"2016","unstructured":"Chen S, Chen X, Xie G, He Y, Yan D, Zheng D, et al. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. Oncotarget. 2016;7:40362\u201376.","journal-title":"Oncotarget"},{"key":"8084_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5114\/aoms.2018.73315","volume":"15","author":"B Zhao","year":"2019","unstructured":"Zhao B, Zhang J, Chen X, Xu H, Huang B, Huang B. Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer. Arch Med Sci. 2019;15:498\u2013503.","journal-title":"Arch Med Sci"},{"key":"8084_CR41","doi-asserted-by":"publisher","first-page":"e0162633","DOI":"10.1371\/journal.pone.0162633","volume":"11","author":"Y He","year":"2016","unstructured":"He Y, Yan D, Zheng D, Hu Z, Li H, Li J. Cell division cycle 6 promotes mitotic slippage and contributes to drug resistance in paclitaxel-treated cancer cells. PLoS ONE. 2016;11:e0162633.","journal-title":"PLoS ONE"},{"key":"8084_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13046-023-02769-z","volume":"42","author":"I Mourkioti","year":"2023","unstructured":"Mourkioti I, Polyzou A, Veroutis D, Theocharous G, Lagopati N, Gentile E, et al. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. J Exp Clin Cancer Res. 2023;42:187.","journal-title":"J Exp Clin Cancer Res"},{"key":"8084_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41388-018-0460-4","volume":"38","author":"X Yu","year":"2019","unstructured":"Yu X, Liu Y, Yin L, Peng Y, Peng Y, Gao Y, et al. Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition. Oncogene. 2019;38:549\u201363.","journal-title":"Oncogene"},{"key":"8084_CR44","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41594-019-0298-7","volume":"26","author":"D Husmann","year":"2019","unstructured":"Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26:880\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"8084_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41556-018-0261-6","volume":"21","author":"J Guo","year":"2019","unstructured":"Guo J, Dai X, Laurent B, Zheng N, Gan W, Zhang J, et al. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019;21:226\u201337.","journal-title":"Nat Cell Biol"},{"key":"8084_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9651","volume":"6","author":"Q Fei","year":"2015","unstructured":"Fei Q, Shang K, Zhang J, Chuai S, Kong D, Zhou T, et al. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat Commun. 2015;6:8651.","journal-title":"Nat Commun"},{"key":"8084_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/A:1018479011340","volume":"15","author":"P Chen","year":"1997","unstructured":"Chen P, Murray T, Uno T, Salgaller M, Reddy R, Ksander B. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997;15:509\u201318.","journal-title":"Clin Exp Metastasis"},{"key":"8084_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1755-148X.2012.00971.x","volume":"25","author":"KG Griewank","year":"2012","unstructured":"Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res. 2012;25:182\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"key":"8084_CR49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1600-0749.2004.00155.x","volume":"17","author":"MS Lagonigro","year":"2004","unstructured":"Lagonigro MS, De Cecco L, Carninci P, Di Stasi D, Ranzani T, Rodolfo M, et al. CTAB-urea method purifies RNA from melanin for cDNA microarray analysis. Pigment Cell Res. 2004;17:312\u20135.","journal-title":"Pigment Cell Res"},{"key":"8084_CR50","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41418-020-00730-7","volume":"28","author":"C Pandiani","year":"2021","unstructured":"Pandiani C, Strub T, Nottet N, Cheli Y, Gambi G, Bille K, et al. Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease. Cell Death Differ. 2021;28:1990\u20132000.","journal-title":"Cell Death Differ"},{"key":"8084_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Wolfgang H. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.","journal-title":"Genome Biol"},{"key":"8084_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"8084_CR53","first-page":"289","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JSTOR. 1995;57:289\u2013300.","journal-title":"JSTOR"},{"key":"8084_CR54","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41388-018-0500-0","volume":"38","author":"J Leclerc","year":"2019","unstructured":"Leclerc J, Garandeau D, Pandiani C, Gaudel C, Bille K, Nottet N, et al. Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells. Oncogene. 2019;38:1282\u201395.","journal-title":"Oncogene"},{"key":"8084_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.molcel.2015.05.009","volume":"59","author":"C Vardabasso","year":"2015","unstructured":"Vardabasso C, Gaspar-Maia A, Hasson D, Punzeler S, Valle-Garcia D, Straub T, et al. Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. Mol Cell. 2015;59:75\u201388.","journal-title":"Mol Cell"},{"key":"8084_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-0259-2","volume":"6","author":"L Bellini","year":"2020","unstructured":"Bellini L, Strub T, Habel N, Pandiani C, Marchetti S, Martel A, et al. Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells. Cell Death Discov. 2020;6:22.","journal-title":"Cell Death Discov"},{"key":"8084_CR57","doi-asserted-by":"crossref","unstructured":"Proteau S, Krossa I, Husser C, Gu\u00e9guinou M, Sella F, Bille K, et al. LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. EMBO Mol Med. 2023;15:e17719.","DOI":"10.15252\/emmm.202317719"},{"key":"8084_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep36539","volume":"6","author":"J Bourseguin","year":"2016","unstructured":"Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, et al. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. Sci Rep. 2016;6:36539.","journal-title":"Sci Rep"},{"key":"8084_CR59","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gad.305854.117","volume":"32","author":"M Ohanna","year":"2018","unstructured":"Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev. 2018;32:448\u201361.","journal-title":"Genes Dev"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08084-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:03:00Z","timestamp":1761321780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08084-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8084"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08084-z","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AE Aplin has ownership interest in patent number 9880150 and has a pending patent, PCT\/US22\/76492. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were performed in accordance with French law and approved by a local institutional ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"754"}}